SK7032001A3 - A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state - Google Patents

A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state Download PDF

Info

Publication number: SK7032001A3
Authority: SK; Slovakia
Prior art keywords: particles; solvent; composition according; less; supercritical
Prior art date: 1998-11-23

Application number

SK703-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Mikael Bisrat

Saeed Moshashee

Hakan Nyqvist

Mustafa Demirbuker

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-23

Filing date

1999-11-22

Publication date

2001-11-06

1999-11-22 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2001-11-06 Publication of SK7032001A3 publication Critical patent/SK7032001A3/sk

Links

239000002245 particle Substances 0.000 title claims abstract description 89
238000000034 method Methods 0.000 title claims abstract description 62
239000002904 solvent Substances 0.000 claims abstract description 39
239000012296 anti-solvent Substances 0.000 claims abstract description 37
239000000203 mixture Substances 0.000 claims abstract description 19
239000013543 active substance Substances 0.000 claims abstract description 18
239000012530 fluid Substances 0.000 claims abstract description 18
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 18
230000004968 inflammatory condition Effects 0.000 claims abstract description 6
230000000172 allergic effect Effects 0.000 claims abstract description 5
208000010668 atopic eczema Diseases 0.000 claims abstract description 5
210000004072 lung Anatomy 0.000 claims abstract description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 39
229910002092 carbon dioxide Inorganic materials 0.000 claims description 19
239000001569 carbon dioxide Substances 0.000 claims description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 13
229960001021 lactose monohydrate Drugs 0.000 claims description 13
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 10
-1 orcrenaline Chemical compound 0.000 claims description 10
229920006395 saturated elastomer Polymers 0.000 claims description 10
239000012453 solvate Substances 0.000 claims description 10
235000000346 sugar Nutrition 0.000 claims description 9
150000002148 esters Chemical class 0.000 claims description 8
102000004196 processed proteins & peptides Human genes 0.000 claims description 8
108090000765 processed proteins & peptides Proteins 0.000 claims description 8
102000004169 proteins and genes Human genes 0.000 claims description 8
108090000623 proteins and genes Proteins 0.000 claims description 8
150000001241 acetals Chemical class 0.000 claims description 7
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 7
239000000812 cholinergic antagonist Substances 0.000 claims description 7
239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 6
229940125388 beta agonist Drugs 0.000 claims description 6
150000002016 disaccharides Chemical class 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
206010009900 Colitis ulcerative Diseases 0.000 claims description 5
208000011231 Crohn disease Diseases 0.000 claims description 5
201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
150000002772 monosaccharides Chemical class 0.000 claims description 5
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 4
208000023819 chronic asthma Diseases 0.000 claims description 4
201000009151 chronic rhinitis Diseases 0.000 claims description 4
150000004676 glycans Chemical class 0.000 claims description 4
229920005862 polyol Polymers 0.000 claims description 4
150000003077 polyols Chemical class 0.000 claims description 4
229920001282 polysaccharide Polymers 0.000 claims description 4
239000005017 polysaccharide Substances 0.000 claims description 4
206010039083 rhinitis Diseases 0.000 claims description 4
150000004043 trisaccharides Chemical class 0.000 claims description 4
230000000694 effects Effects 0.000 claims description 3
229920001542 oligosaccharide Polymers 0.000 claims description 3
150000002482 oligosaccharides Chemical class 0.000 claims description 3
150000008163 sugars Chemical class 0.000 claims description 3
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 2
NUBLQEKABJXICM-FQEVSTJZSA-N (1r)-1-(4-amino-3,5-dichlorophenyl)-2-[6-(2-pyridin-2-ylethoxy)hexylamino]ethanol Chemical compound C1=C(Cl)C(N)=C(Cl)C=C1[C@@H](O)CNCCCCCCOCCC1=CC=CC=N1 NUBLQEKABJXICM-FQEVSTJZSA-N 0.000 claims description 2
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims description 2
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 2
229960004620 bitolterol Drugs 0.000 claims description 2
FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 claims description 2
JBRBWHCVRGURBA-UHFFFAOYSA-N broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 claims description 2
229950008847 broxaterol Drugs 0.000 claims description 2
229960001117 clenbuterol Drugs 0.000 claims description 2
STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims description 2
150000004683 dihydrates Chemical class 0.000 claims description 2
229960001022 fenoterol Drugs 0.000 claims description 2
LSLYOANBFKQKPT-UHFFFAOYSA-N fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 claims description 2
229960002848 formoterol Drugs 0.000 claims description 2
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 2
JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 claims description 2
229950004407 mabuterol Drugs 0.000 claims description 2
150000004682 monohydrates Chemical class 0.000 claims description 2
229950004618 picumeterol Drugs 0.000 claims description 2
229960005414 pirbuterol Drugs 0.000 claims description 2
239000002798 polar solvent Substances 0.000 claims description 2
229960002288 procaterol Drugs 0.000 claims description 2
FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 claims description 2
229960002720 reproterol Drugs 0.000 claims description 2
WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 claims description 2
229960001457 rimiterol Drugs 0.000 claims description 2
IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 claims description 2
229960002052 salbutamol Drugs 0.000 claims description 2
229960004017 salmeterol Drugs 0.000 claims description 2
229960000195 terbutaline Drugs 0.000 claims description 2
150000004684 trihydrates Chemical class 0.000 claims description 2
238000006243 chemical reaction Methods 0.000 claims 4
239000003814 drug Substances 0.000 claims 3
206010027654 Allergic conditions Diseases 0.000 claims 1
238000002955 isolation Methods 0.000 claims 1
238000002425 crystallisation Methods 0.000 abstract description 2
230000008025 crystallization Effects 0.000 abstract description 2
238000009472 formulation Methods 0.000 abstract 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 4
239000000126 substance Substances 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000002876 beta blocker Substances 0.000 description 3
229920003063 hydroxymethyl cellulose Polymers 0.000 description 3
229940031574 hydroxymethyl cellulose Drugs 0.000 description 3
208000028774 intestinal disease Diseases 0.000 description 3
239000013618 particulate matter Substances 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
229920000896 Ethulose Polymers 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 2
239000005977 Ethylene Substances 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
229910018503 SF6 Inorganic materials 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 2
239000001761 ethyl methyl cellulose Substances 0.000 description 2
235000010944 ethyl methyl cellulose Nutrition 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000008101 lactose Substances 0.000 description 2
VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
238000005086 pumping Methods 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
229950004432 rofleponide Drugs 0.000 description 2
IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 2
238000009738 saturating Methods 0.000 description 2
238000001694 spray drying Methods 0.000 description 2
SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 2
229960000909 sulfur hexafluoride Drugs 0.000 description 2
229910052724 xenon Inorganic materials 0.000 description 2
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
DXEXNWDGDYUITL-FXSSSKFRSA-N Tipredane Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000005233 alkylalcohol group Chemical group 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
229950000210 beclometasone dipropionate Drugs 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
229940124748 beta 2 agonist Drugs 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
229960003728 ciclesonide Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229960003469 flumetasone Drugs 0.000 description 1
WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
229960000676 flunisolide Drugs 0.000 description 1
229940043075 fluocinolone Drugs 0.000 description 1
229960002714 fluticasone Drugs 0.000 description 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
229960000289 fluticasone propionate Drugs 0.000 description 1
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229960001317 isoprenaline Drugs 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960001664 mometasone Drugs 0.000 description 1
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
229960002744 mometasone furoate Drugs 0.000 description 1
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
229960002657 orciprenaline Drugs 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
239000001294 propane Substances 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229950001669 tipredane Drugs 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Physical Or Chemical Processes And Apparatus (AREA)
Oxygen, Ozone, And Oxides In General (AREA)
Inorganic Compounds Of Heavy Metals (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Recrystallisation Techniques (AREA)

SK703-2001A 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state SK7032001A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9804000A SE9804000D0 (sv)	1998-11-23	1998-11-23	New composition of matter
PCT/SE1999/002154 WO2000030614A1 (en)	1998-11-23	1999-11-22	A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Publications (1)

Publication Number	Publication Date
SK7032001A3 true SK7032001A3 (en)	2001-11-06

Family

ID=20413377

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK703-2001A SK7032001A3 (en)	1998-11-23	1999-11-22	A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Country Status (27)

Country	Link
US (1)	US6475524B1 (da)
EP (1)	EP1133285B1 (da)
JP (1)	JP4447169B2 (da)
KR (1)	KR100697780B1 (da)
CN (1)	CN1198592C (da)
AT (1)	ATE318583T1 (da)
AU (1)	AU767313B2 (da)
BR (1)	BR9915592A (da)
CA (1)	CA2349633C (da)
CY (1)	CY1105609T1 (da)
CZ (1)	CZ20011778A3 (da)
DE (1)	DE69930158T2 (da)
DK (1)	DK1133285T3 (da)
EE (1)	EE200100275A (da)
ES (1)	ES2258865T3 (da)
HU (1)	HUP0104182A2 (da)
IL (2)	IL143040A0 (da)
IS (1)	IS5946A (da)
NO (1)	NO20012514L (da)
NZ (1)	NZ511494A (da)
PL (1)	PL348523A1 (da)
PT (1)	PT1133285E (da)
SE (1)	SE9804000D0 (da)
SK (1)	SK7032001A3 (da)
TR (1)	TR200101424T2 (da)
WO (1)	WO2000030614A1 (da)
ZA (1)	ZA200103946B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0016002D0 (en) *	2000-06-29	2000-08-23	Glaxo Group Ltd	Novel process for preparing crystalline particles
DE10062712A1 (de) *	2000-12-15	2002-06-20	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
EP1354581A4 (en) *	2000-12-26	2007-07-04	Takeda Pharmaceutical	POROUS SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF
EP1401563B2 (en) *	2001-07-02	2015-09-16	Micro & Nano Materials SAGL	Process for the production of micro and/or nano particles
GB0126716D0 (en) *	2001-11-07	2002-01-02	Advanced Phytonics Ltd	Method for the production of particles
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
RU2006132043A (ru) *	2004-02-06	2008-03-20	МЕДА Фарма ГмбХ унд Ко.КГ (DE)	Комбинация и фармацевтический препарат для лечения ринита
TWI341836B (en)	2004-03-11	2011-05-11	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
US7968575B2 (en)	2004-05-05	2011-06-28	Renopharm Ltd.	Nitric oxide donors and uses thereof
US7498445B2 (en)	2004-05-05	2009-03-03	Renopharm Ltd.	Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US8134010B2 (en)	2004-05-05	2012-03-13	Renopharm Ltd.	Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
EP1753734A1 (en)	2004-05-05	2007-02-21	Renopharm Ltd.	Nitric oxide donors and uses thereof
WO2006023460A2 (en)	2004-08-16	2006-03-02	Theravance, Inc.	COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP5000095B2 (ja) *	2005-03-11	2012-08-15	花王株式会社	有機結晶粒子の製造方法
AU2006272438B2 (en)	2005-07-15	2011-08-04	Map Pharmaceuticals, Inc.	Method of particle formation
DE102006030166A1 (de) *	2006-06-29	2008-01-10	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tempern
WO2009047935A1 (ja) *	2007-10-12	2009-04-16	Ono Pharmaceutical Co., Ltd.	微粒子
US8585943B2 (en) *	2007-12-07	2013-11-19	Xspray Microparticles Ab	Method and arrangement for the production of particles
JP5138670B2 (ja) *	2009-01-30	2013-02-06	三洋化成工業株式会社	樹脂粒子およびその製造方法
EP2393488B1 (en)	2009-02-06	2019-06-19	University Of Southern California	Therapeutic compositions comprising monoterpenes
KR101742252B1 (ko)	2009-07-15	2017-05-31	세라밴스 바이오파마 알앤디 아이피, 엘엘씨	비페닐 화합물의 결정질 유리 염기형
US8507734B2 (en)	2010-03-03	2013-08-13	Neonc Technologies Inc.	Pharmaceutical compositions comprising monoterpenes
EP3173080B1 (en)	2010-08-27	2019-12-11	Neonc Technologies Inc.	Pharmaceutical compositions comprising derivatives of perillyl alcohol
US20160038600A1 (en)	2012-08-03	2016-02-11	Neonc Technologies Inc.	Pharmaceutical compositions comprising poh derivatives
CN105616391B (zh)	2010-12-17	2021-03-19	尼昂克技术公司	使用异紫苏醇的方法和装置
EP2968312B1 (en)	2013-03-15	2018-01-31	Verona Pharma PLC	Drug combination
GB201402556D0 (en)	2014-02-13	2014-04-02	Crystec Ltd	Improvements relating to inhalable particles
PL3231444T3 (pl)	2014-05-12	2020-05-18	Verona Pharma Plc	Nowe leczenie
KR20170131405A (ko)	2015-02-12	2017-11-29	네온씨 테크놀로지스, 아이엔씨.	페릴릴 알코올 유도체를 포함하는 의약 조성물
DK3547836T3 (da)	2016-11-30	2024-11-18	Univ Southern California	Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer
DK3749291T3 (da)	2018-02-08	2024-04-08	Univ Southern California	Fremgangsmåder til permeabilisering af blod-hjerne-barrieren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9101090D0 (sv)	1991-04-11	1991-04-11	Astra Ab	Process for conditioning of water-soluble substances
SE9302777D0 (sv) *	1993-08-27	1993-08-27	Astra Ab	Process for conditioning substances
US5639441A (en) *	1992-03-06	1997-06-17	Board Of Regents Of University Of Colorado	Methods for fine particle formation
GB9313642D0 (en)	1993-07-01	1993-08-18	Glaxo Group Ltd	Method and apparatus for the formation of particles
GB9413202D0 (en) *	1994-06-30	1994-08-24	Univ Bradford	Method and apparatus for the formation of particles
EP0817620B1 (en) *	1995-03-28	2002-01-30	Fidia Advanced Biopolymers, S.R.L.	Nanospheres comprising a biocompatible polysaccharide
WO1998041193A1 (en)	1997-03-20	1998-09-24	Schering Corporation	Preparation of powder agglomerates

1998
- 1998-11-23 SE SE9804000A patent/SE9804000D0/xx unknown
1999
- 1999-11-22 CN CNB998136093A patent/CN1198592C/zh not_active Expired - Fee Related
- 1999-11-22 JP JP2000583498A patent/JP4447169B2/ja not_active Expired - Fee Related
- 1999-11-22 NZ NZ511494A patent/NZ511494A/en not_active IP Right Cessation
- 1999-11-22 AU AU20104/00A patent/AU767313B2/en not_active Ceased
- 1999-11-22 SK SK703-2001A patent/SK7032001A3/sk unknown
- 1999-11-22 CZ CZ20011778A patent/CZ20011778A3/cs unknown
- 1999-11-22 CA CA002349633A patent/CA2349633C/en not_active Expired - Fee Related
- 1999-11-22 WO PCT/SE1999/002154 patent/WO2000030614A1/en not_active Ceased
- 1999-11-22 ES ES99963731T patent/ES2258865T3/es not_active Expired - Lifetime
- 1999-11-22 EP EP99963731A patent/EP1133285B1/en not_active Expired - Lifetime
- 1999-11-22 DK DK99963731T patent/DK1133285T3/da active
- 1999-11-22 PT PT99963731T patent/PT1133285E/pt unknown
- 1999-11-22 IL IL14304099A patent/IL143040A0/xx unknown
- 1999-11-22 US US09/486,675 patent/US6475524B1/en not_active Expired - Fee Related
- 1999-11-22 BR BR9915592-3A patent/BR9915592A/pt not_active Application Discontinuation
- 1999-11-22 DE DE69930158T patent/DE69930158T2/de not_active Expired - Lifetime
- 1999-11-22 PL PL99348523A patent/PL348523A1/xx not_active Application Discontinuation
- 1999-11-22 KR KR1020017006444A patent/KR100697780B1/ko not_active Expired - Fee Related
- 1999-11-22 AT AT99963731T patent/ATE318583T1/de not_active IP Right Cessation
- 1999-11-22 EE EEP200100275A patent/EE200100275A/xx unknown
- 1999-11-22 TR TR2001/01424T patent/TR200101424T2/xx unknown
- 1999-11-22 HU HU0104182A patent/HUP0104182A2/hu unknown
2001
- 2001-05-08 IL IL143040A patent/IL143040A/en not_active IP Right Cessation
- 2001-05-15 ZA ZA200103946A patent/ZA200103946B/xx unknown
- 2001-05-18 IS IS5946A patent/IS5946A/is unknown
- 2001-05-22 NO NO20012514A patent/NO20012514L/no not_active Application Discontinuation
2006
- 2006-05-17 CY CY20061100642T patent/CY1105609T1/el unknown

Also Published As

Publication number	Publication date
EE200100275A (et)	2002-10-15
CA2349633A1 (en)	2000-06-02
NZ511494A (en)	2003-11-28
PL348523A1 (en)	2002-06-03
ES2258865T3 (es)	2006-09-01
JP4447169B2 (ja)	2010-04-07
KR20010080534A (ko)	2001-08-22
CZ20011778A3 (cs)	2001-08-15
ZA200103946B (en)	2002-10-30
CA2349633C (en)	2009-06-02
IL143040A (en)	2009-09-01
SE9804000D0 (sv)	1998-11-23
DE69930158T2 (de)	2006-11-16
KR100697780B1 (ko)	2007-03-21
BR9915592A (pt)	2001-08-07
IS5946A (is)	2001-05-18
AU767313B2 (en)	2003-11-06
WO2000030614A1 (en)	2000-06-02
AU2010400A (en)	2000-06-13
HUP0104182A2 (hu)	2002-03-28
JP2002530319A (ja)	2002-09-17
EP1133285B1 (en)	2006-03-01
NO20012514L (no)	2001-07-19
NO20012514D0 (no)	2001-05-22
CY1105609T1 (el)	2010-07-28
US6475524B1 (en)	2002-11-05
PT1133285E (pt)	2006-06-30
DK1133285T3 (da)	2006-06-06
TR200101424T2 (tr)	2001-12-21
DE69930158D1 (de)	2006-04-27
CN1198592C (zh)	2005-04-27
ATE318583T1 (de)	2006-03-15
CN1328447A (zh)	2001-12-26
IL143040A0 (en)	2002-04-21
EP1133285A1 (en)	2001-09-19

Publication	Publication Date	Title
SK7032001A3 (en)	2001-11-06	A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
CA2348084C (en)	2009-01-06	Crystallisation using supercritical or subcritical fluids
US5874063A (en)	1999-02-23	Pharmaceutical formulation
JP2002530318A5 (da)	2007-01-18
DE69426934T2 (de)	2001-09-13	Verfahren zur konditionierung von substanzen
KR100386055B1 (ko)	2003-06-09	분말 응집물의 제조방법
US20020081266A1 (en)	2002-06-27	Spray dried powders for pulmonary or nasal administration
MXPA05006441A (es)	2005-09-08	Preparacion de suspensiones acuosas esteriles que comprenden ingredientes activos cristalinos micronizados para inhalacion.
JP2005519095A (ja)	2005-06-30	新規製剤
RU2001117234A (ru)	2003-04-20	Способ получения частиц с аморфной и/или метастабильной кристаллической областью, переведенной в кристаллическое состояние
HK1021323B (en)	2005-06-03	Preparation of powder agglomerates
HK1061359B (en)	2009-03-06	Dosage form of powder agglomerates